icon-folder.gif   Conference Reports for NATAP  
  EASL 45th Annual Meeting
April 14-18, 2010
Vienna, Austria
Back grey_arrow_rt.gif
Sustained Virologic Response following RG7128 1500 mg BID PEG-IFN/RBV for 28 days in HCV Genotype 2/3 prior non-responders
  Reported by Jules Levin
EASL Apr 14-18 2010 Vienna Austria
EJ Gane, M Rodriguez-Torres, DE Nelson, IM Jacobson, JG McHutchison, R Hyland, G Hill, E Albanis, B Symonds, MM Berrey
in HCV GT 2/3 prior non-responders

28 days RG7128 added to SOC has potent antiviral efficacy in HCV GT 2 and GT 3 patients who have previously failed SOC:
- RVR 95%
- SVR 65%
Longer treatment duration studies needed to determine the optimal duration of RG7128/SOC for Rx-naive and experienced GT 2/3 patients
RG7128 has preserved potency across viral genotypes due to the consistent mechanism of action of chain- terminating nucleoside analogs